ch.oddb.org
 
Analysen | Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
 Sie befinden sich in - Home - Fachinformation zu Repatha
Fachinformation zu Repatha:Amgen Switzerland AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info.
C10AX13 - EvolocumabATC-DDD Version 2016. Source: WHO
C - Cardiovascular System
 
C10 - Lipid Modifying Agents
 

The DDDs are based on the treatment of hypercholesterolemia.

C10A - Lipid Modifying Agents, plain

Combinations of different cholesterol and triglyceride reducers are classified at separate 5th levels using the corresponding 50-series. The following ranking according to the ATC codes is used: Substances classified in ATC-group C10AA take precedence over C10AB etc.
Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.

C10AX - Other Lipid Modifying Agents

This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.
Sulodexide is classified in B01AB.

The DDD for evolocumab is based on dosing every second week.

C10AX13 - Evolocumab
StärkeAdm.RouteNote
10 mgP 
LGPL2017 ywesee.com, Commit-ID
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home